However, given the association of hereditary predisposition syndromes in patients with melanoma and/or mesothelioma with renal neoplasia, universal screening may be warranted in this patient population with a panel that includes BAP1, MITF, and FLCN. This evidence concerns the gene FLCN and melanoma.